Registration - In-house Corporation

Pfizer Canada ULC / An Van Gerven, President

Registration Information

In-house Corporation name: Pfizer Canada ULC
Responsible Officer Name: An Van Gerven, President
Responsible Officer Change History
Initial registration start date: 2007-04-27
Registration status: Active
Registration Number: 960525-15283

Associated Communications

Total Number of Communication Reports: 329

Monthly communication reports in the last 6 months: 1

Version 14 of 42 (2014-05-23 to 2014-12-31)

Registration versions:

Version 14 of 42 (2014-05-23 to 2014-12-31)

Lobbying Information

Subject Matters

Consumer Issues
Health
Industry
Intellectual Property
International Relations
International Trade
Regional Development
Research and Development
Science and Technology
Taxation and Finance

Subject matters added through a monthly communication report

Government Procurement

Subject Matter Details

Grant, Contribution or Other Financial Benefit

National Immunization Strategy. Advocacy to seek continued funding in vaccines.

Legislative Proposal, Bill or Resolution, Regulation

Patent Act as it relates to the eventual implementation of the Comprehensive Economic Trade Agreement (CETA) and Intellectual property protection provisions.
The international trade negotiations under the Comprehensive Economic Trade Agreement (CETA) and the Tans-Pacific Partnership (TPP) as it relates to potential legislative or regulatory changes of Canada's intellectual property regime for pharmaceutical products (Patent Act).
The upcoming Food and Drugs Act Modernization legislative proposal (Act and Regulations) as it relates to improving the efficiency of the drug review and approval process.

Policies or Program

Common Drug Review as it relates to reimbursement recommendations decision-making process and framework.
Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries
Science and Technology Strategy, Advantage Canada or any Government policy or program initiatives to help support more Research and Development conducted in Canada, advocate for the development of a coordinated life science strategy

Policies or Program, Regulation

Subsequent Entry Biologics (SEBs) and Orphan Drugs framework: seeking an approval framework supported and protected by Regulations in harmonization with other developed countries

Regulation

Patented Medicine Prices Review Board (PMPRB) Regulations as it relates to reporting requirements and pricing guidelines.
Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for therapeutic products.

Communication Techniques

Written communication
Grass-roots communication
As part of Industry Associations and Delegations eg. Rx&D, BIOTECanada, Chamber of Commerce

Government Institutions

Aboriginal Affairs and Northern Development Canada
Atlantic Canada Opportunities Agency (ACOA)
Canada Economic Development for Quebec Regions
Canada Revenue Agency (CRA)
Canadian Institutes of Health Research (CIHR)
Employment and Social Development Canada (ESDC)
Federal Office of Regional Development – Quebec (FORD[Q])
Finance Canada (FIN)
Foreign Affairs, Trade and Development Canada
Health Canada (HC)
House of Commons
Industry Canada
Justice Canada (JC)
Members of the House of Commons
National Defence (DND)
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)
Privy Council Office (PCO)
Public Health Agency of Canada (PHAC)
Public Works and Government Services Canada
Revenue Canada (RC)
Senate of Canada
Treasury Board Of Canada Secretariat (TBS)
Veterans Affairs Canada (VAC)
Western Economic Diversification Canada (WD)

In-house Corporation Details

Description of activities

Pfizer's mission is to discover and develop innovative medicines, vaccines and other products to improve the quality of life of people and animals.

Responsible officer name and position during the period of this registration

John Helou, Président et chef de la direction

Government funding

No government funding was received during the last completed financial year.

In-house Corporation Contact Information

Address:
17,300 TRANS-CANADA HIGHWAY
KIRKLAND, QC H9J 2M5
Canada

Telephone number: 514-693-4563
Fax number: 514-426-6921

Parent Company Information

PFIZER INC
- 235 EAST 42ND STREET
  NEW YORK, NY 10017-5755
  United States of America

Subsidiary Beneficiary Information

Pfizer Canada ULC does not have any subsidiaries that could have a direct interest in the outcome of the undertaking

Lobbyists Details

Senior Officers whose lobbying activities represent less than 20% of their Duties

Dr. Ghislain Boudreau, Vice President, Public Affairs | No public offices held
John Helou, Président et chef de la direction | No public offices held
Darren Noseworthy, Vice President & General Counsel | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

Denise Cloutier, National Director, Health & Economic Policy | No public offices held
Steven Hogue, Associate Director, Federal Relations & Public Policies | Public offices held

Pfizer Canada ULC

The following names have been used on or after July 2, 2008

Name	From	To
Pfizer Canada ULC	2009-05-13	current

The following names have been used before July 2, 2008

Pfizer Canada ULC

Pfizer Canada ULC

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)
An Van Gerven	2025-01-01	Current
Najah Sampson	2022-05-16	2025-01-01
Cole C. Pinnow	2020-01-06	2022-05-16
John Helou	2012-01-30	2020-01-06
Paul Lévesque	2007-04-27	2012-01-30

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
Deputy Director of Communications Office of the Prime Minister of Canada, Communications	November 2002 to December 2003	Not a designated office
Special Assistant (Quebec Issues) Office of the Prime Minister of Canada, Operations	July 2001 to November 2002	Not a designated office
Special Assistant (Quebec and Atlantic Issues) Department of Fisheries & Oceans, Minister's Office	August 1999 to July 2001	Not a designated office
Special Assistant (Quebec and Atlantic Issues) Canada Customs and Revenue Agency, Minister's Office	September 1998 to August 1999	Not a designated office

Date Modified:: 2025-04-30

Search and menus

Language selection

Registration - In-house Corporation

Pfizer Canada ULC / An Van Gerven, President

Registration Information

Associated Communications

Version 14 of 42 (2014-05-23 to 2014-12-31)

Version 14 of 42 (2014-05-23 to 2014-12-31)

Subject Matters

Subject matters added through a monthly communication report

Subject Matter Details

Grant, Contribution or Other Financial Benefit

Legislative Proposal, Bill or Resolution, Regulation

Policies or Program

Policies or Program, Regulation

Regulation

Communication Techniques

Government Institutions

Description of activities

Responsible officer name and position during the period of this registration

Government funding

In-house Corporation Contact Information

Parent Company Information

Subsidiary Beneficiary Information

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties